ArticleRheumatology (Oxford, England)2018
Evaluation of damage in giant cell arteritis.
Article in Rheumatology (Oxford, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04204876 (Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Osteoporosis and fractures in systemic vasculitides: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Pooled it
- Management of Takayasu Arteritis - A 2026 Update.Current rheumatology reports · 2026Review
- Impact of immunosuppressive therapy and clinical risk factors on the prevalence of low bone mineral density in rheumatic diseases.Frontiers in medicine · 2026Article
- Assessment of damage in Takayasu's arteritis.Rheumatology (Oxford, England) · 2025Observational
- Clinical Manifestations and Prognosis of Giant Cell Arteritis: A Retrospective Cohort Study.Doklady. Biochemistry and biophysics · 2024Article
- Giant cell arteritis: reviewing the advancing diagnostics and management.Eye (London, England) · 2023Review
- Looking ahead: giant-cell arteritis in 10 years time.Therapeutic advances in musculoskeletal disease · 2022Review
- The Impact of High Dose Glucocorticoids on Bone Health and Fracture Risk in Systemic Vasculitides.Frontiers in endocrinology · 2022Review
- Long-term follow-up of 89 patients with giant cell arteritis: a retrospective observational study on disease characteristics, flares and organ damage.Rheumatology international · 2021Observational
- Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.Nature reviews. Rheumatology · 2020Review
- Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis-Similarities and Differences.Current rheumatology reports · 2020Review
- [Long-term complications, monitoring and interventional treatment of large vessel vasculitis].Zeitschrift fur Rheumatologie · 2020Review
- Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions.Arthritis research & therapy · 2020Article
- Clinical symptoms and associated vascular imaging findings in Takayasu's arteritis compared to giant cell arteritis.Annals of the rheumatic diseases · 2020Article
- Osteoporosis in Rheumatic Diseases.International journal of molecular sciences · 2019Review
- Does leflunomide have a role in giant cell arteritis? An open-label study.Clinical rheumatology · 2019Observational
- Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management.Drugs & aging · 2019Review
- Metabolic bone health considerations in giant cell arteritis and polymyalgia rheumatica.Women's health (London, England)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 11 institutions in 2 countries.
Funding
Abstract
Objectives: To evaluate damage and variables associated with damage in GCA. Methods: Patients with GCA enrolled in a prospective, multicentre, longitudinal study were included. Per-protocol assessments were made with the Vasculitis Damage Index and the Large-Vessel Vasculitis Index of Damage. Results: The study included 204 patients: 156 women (76%), mean age at diagnosis 71.3 years (s.d. 8.3), mean follow-up of 3.5 years (s.d. 1.9). One or more damage item was present in 54% at baseline and 79% at the last follow-up on the Vasculitis Damage Index, and 60% at baseline and 82% at the last follow-up on the Large-Vessel Vasculitis Index of Damage. The most frequently observed damage items were large-artery complications (29% cohort) and ocular (22%). Among 117 patients with new damage, most new items were ocular (63 patients), cardiac/vascular (48) and musculoskeletal (34). Of these, treatment-associated items were frequently observed, including cataracts (46 patients), osteoporosis (22) and weight gain (22). Disease-associated new damage included ischaemic optic neuropathy (3 patients), limb claudication (13), arterial occlusions (10) and damage requiring vascular intervention (10). In univariate analysis, the risk of damage increased 22% for every additional year of disease duration [odds ratio (OR) 1.22 (95% CI 1.04, 1.45)]. In 94 patients enrolled within ⩽90 days of diagnosis of GCA, the risk of new damage at the last follow-up decreased 30% for each additional relapse [OR 0.70 (95% CI 0.51, 0.97)]. Conclusions: Large-artery complications and ocular manifestations are the most commonly occurring items of damage in GCA. Most new damage is associated with treatment. These findings emphasize the cumulative burden of disease in GCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.